Download PDF
Der Klinikarzt 2009; 38(10): 443-451
DOI: 10.1055/s-0029-1243265
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Neue Antikoagulantien – Gleichwertig oder wirksamer, gleich oder besser verträglich?

Novel anticoagulants – Of equal value or more, effective, equally well or better tolerated?Job Harenberg1
  • 1Institut für Klinische Pharmakologie Mannheim, Ruprecht–Karls–Universität Heidelberg, Mannheim
Further Information

Publication History

Publication Date:
12 November 2009 (online)

Also available at
    Permissions and Reprints

Die neuen oralen Antikoagulantien Dabigatran und Rivaroxaban sind nach elektivem Knie– und Hüftgelenksersatz seit kurzem zur postoperativen Thromboembolieprophylaxe zugelassen. Dabigatran zeigte bei Patienten mit Vorhofflimmern erstmals eine bessere Wirksamkeit und Verträglichkeit als INR–adjustiertes Warfarin zur Prophylaxe zerebraler und nicht–zerebraler Embolien. Zu dieser Indikation werden die Studien mit Rivaroxaban und Apixaban im nächsten Jahr beendet.

Bei den systemisch verabreichten neuen Antikoagulantien zeigen erste Daten eine verbesserte Wirksamkeit des intravenös verabreichten direkten Faktor–Xa–Hemmers Otamixaban bei Patienten mit instabiler Angina.

Das sehr lang wirkende subkutan verabreichte Idrabiotaparinux wird bei Patienten mit Lungenembolie geprüft. Von Bedeutung ist die Neutralisierung des antikoagulanten Effektes und die Elimination der Substanz durch intravenös verabreichtes Avidin, ein Hühnereiweiß.

Initial clinical trials have shown that new oral anticoagulants yield at least equal or even more effective and at least equally or better tolerated results than INR–adjusted coumarins. So far, data have been published for Dabigatran for atrial fibrillation. Further results for Rivaroxaban and Apixaban for this will be shortly available. Initial data for the systemically applied new anticoagulants show an improved efficacy of the intravenously applied direct factor Xa inhibitor Otamixaban in patients with unstable angina pectoris.

The very long–acting subcutaneously administered Idrabiotaparinux is being tried out on pulmonary embolism patients. The neutralisation of the anticoagulant effect and the elimination of the substance by means of intravenously administered Avidin (an ovalbumin) are important.

Key words

New oral anticoagulants - coumarin - Dabigatran - Rivaroxaban - Apixaban - Otamixaban - Idrabiotaparinux - Avidin

Literatur

  • 1 Agnelli G, Gallus A, Goldhaber SZ. et al. . Treatment of Proximal Deep–Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59–7939): The ODIXa–DVT (Oral Direct Factor XaInhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep–Vein Thrombosis) Study.  Circulation. 2007;  116 180-187
    CrossrefPubMedGoogle Scholar
  • 2 Alexander JH, Yang H, Becker RC. et al. . First experience with direct, selective factor Xa inhibition in patients with non–ST–elevation acute coronary syndromes: results of the XaNADU–ACS Trial.  J Thromb Haemost. 2004;  3 439-447
    PubMedGoogle Scholar
  • 3 Amadeus Investigators.. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open–label, non–inferiority trial.  Lancet. 2008;  371 315-321
    CrossrefPubMedGoogle Scholar
  • 4 APPRAISE Steering Committee and Investigators. . Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial.  Circulation. 2009;  119 2877-2885
    CrossrefPubMedGoogle Scholar
  • 5 AWMF–Leitlinien–Register Nr. 003/001, Prophylaxe der venösen Thromboembolie (VTE) Finale Version vom 18. .März 2009, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. 2009
    PubMedGoogle Scholar
  • 6 Büller H, Deitchman D, Prins M. et al. . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose–ranging study.  J Thromb Haemost. 2008;  6 1313-1318
    CrossrefPubMedGoogle Scholar
  • 7 Büller HR, Lensing AW, Prins MH. et al. . A dose–ranging study evaluating once–daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute Study symptomatic deep vein thrombosis: the Einstein_DVT Dose–Ranging Study.  Blood. 2008;  112 2242-2247
    CrossrefPubMedGoogle Scholar
  • 8 Cohen M, Deepak L, Bhatt JH. et al. . Randomized, Double–Blind, Dose–Ranging Study of Otamixaban, a Novel, Parenteral, Short–Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA–PCI Trial.  Circulation. 2007;  115 2642-2651
    CrossrefPubMedGoogle Scholar
  • 9 Colwell CW, Berkowitz SD, Davidson BL. et al. . Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement.  J Thromb Haemost. 2003;  1 2119-2130
    CrossrefPubMedGoogle Scholar
  • 10 Colwell CW, Berkowitz SD, Lieberman JR. et al. . Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty.  J Bone Joint Surg. 2005;  87 2169-2177
    CrossrefPubMedGoogle Scholar
  • 11 Connolly SJ, Ezekowitz MD, Yusuf S. et al. . Dabigatran versus Warfarin in Patients with Atrial Fibrillation.  N Engl J Med. 2009;  361 1-13
    CrossrefPubMedGoogle Scholar
  • 12 Eriksson BI, Agnelli G, Cohen AT.. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.  J Thromb Haemost. 2003;  1 2490-2496
    CrossrefPubMedGoogle Scholar
  • 13 Eriksson BI, Bergqvist D, Kälebo P. et al. . Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.  The Lancet. 2002;  360 1441-1447
    CrossrefPubMedGoogle Scholar
  • 14 Eriksson BI, Borris L, Dahl OE. et al. . Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement.  J Thromb Haemost. 2006;  4 121-128
    PubMedGoogle Scholar
  • 15 Eriksson BI, Borris LC, Dahl OE. et al. . A Once–Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59–7939), for Thromboprophylaxis After Total Hip Replacement.  Circulation. 2006;  114 2374-2381
    CrossrefPubMedGoogle Scholar
  • 16 Eriksson BI, Borris LC, Dahl OE. et al. . Dose–escalation study of rivaroxaban (BAY 59–7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement.  Thromb Res. 2007;  120 685-693
    CrossrefPubMedGoogle Scholar
  • 17 Eriksson BI, Borris LC, Friedman RJ. et al. . Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty.  N Engl J Med. 2008;  358 2765-2775
    CrossrefPubMedGoogle Scholar
  • 18 Eriksson BI, Dahl OE, Ahnfelt L. et al. . Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.  J Thromb Haemost. 2004;  2 1573-1580
    CrossrefPubMedGoogle Scholar
  • 19 Eriksson BI, Dahl OE, Büller HR. et al. . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.  J Thromb Haemost. 2004;  3 103-111
    PubMedGoogle Scholar
  • 20 Eriksson BI, Dahl OE, Rosencher N. et al. . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double–blind, non–inferiority trial.  The Lancet. 2007;  370 949-956
    CrossrefPubMedGoogle Scholar
  • 21 Eriksson BI, Dahl OE, Rosencher N. et al. . Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE–MODEL randomized trial.  J Thromb Haemost. 2007;  5 2178-2185
    CrossrefPubMedGoogle Scholar
  • 22 Eriksson H, Wählander K, Gustafsson D. et al. . A randomized, controlled, dose–guiding study of the oral directthrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.  J Thromb Haemost. 2003;  1 41-47
    CrossrefPubMedGoogle Scholar
  • 23 Eriksson UG, Mandema JW, Karlsson MO. et al. . Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran.  Clin Pharmacokinet. 2003;  42 687-701
    CrossrefPubMedGoogle Scholar
  • 24 Fiessinger JN, Huisman MV, Davidson BL. et al. . Ximelagatran vs Low–Molecular–Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial.  JAMA. 2005;  293 681-689
    CrossrefPubMedGoogle Scholar
  • 25 Francis CW, Berkowitz SC, Comp PC. et al. . Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement.  New Engl J Med. 2003;  349 1703-1712
    CrossrefPubMedGoogle Scholar
  • 26 Francis CW, Davidson BL, Berkowith SD. et al. . Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty.  Ann Int Med. 2002;  137 648-655
    PubMedGoogle Scholar
  • 27 Gage BF, Waterman AD, Shannon W. et al. . Validation of Clinical Classification Schemesfor Predicting Stroke Results From the National Registry of Atrial Fibrillation.  JAMA. 2001;  285 2864-2670
    CrossrefPubMedGoogle Scholar
  • 28 Geerts WH, Bergqvist D, Pineo GF. et al. . Prevention of Venous Thromboembolism.  CHEST. 2008;  133 381-453
    CrossrefPubMedGoogle Scholar
  • 29 Ginsberg JS, Davidson BL, Philip C. et al. . Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery.  J Arthroplasty. 2009;  24 1-9
    CrossrefPubMedGoogle Scholar
  • 30 Harenberg J, Wehling M.. Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIa.  Semin Thromb Hemost. 2008;  34 39-57
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Harenberg J.. New Anticoagulants in Atrial Fibrillation.  Semin Thromb Hemost. 2009;  35 574-586
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Heit JA, Colwell CW, Francis CW. et al. . Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement.  Arch Intern Med. 2001;  161 2215-2221
    CrossrefPubMedGoogle Scholar
  • 33 Kakkar AK, Brenner B, Dahl OE. et al. . Extended duration rivaroxaban versus short–termenoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double–blind, randomised controlled trial.  The Lancet. 2008;  372 31-39
    CrossrefPubMedGoogle Scholar
  • 34 Kearon C, Kahn S, Agnelli G. et al. . Antithrombotic Therapy for Venous Thromboembolic Disease.  CHEST. 2008;  133 454-545
    CrossrefPubMedGoogle Scholar
  • 35 Kubitza D, Becka M, Wensing G. et al. . Safety, pharmacodynamcis, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects.  Eur J Clin Pharmacol. 2005;  61 873-880
    CrossrefPubMedGoogle Scholar
  • 36 Lassen MR, Ageno W, Borris LC. et al. . Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty.  N Engl J Med. 2008;  358 2276-2286
    CrossrefPubMedGoogle Scholar
  • 37 Lassen MR, Davidson BL, Gallus A. et al. . The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.  J Thromb Haemost. 2007;  5 2368-2375
    CrossrefPubMedGoogle Scholar
  • 38 Lassen MR, Raskob GE, Gallus A. et al. . Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement.  N Engl J Med. 2009;  361 594-604
    CrossrefPubMedGoogle Scholar
  • 39 Mega JL, Braunwald E, Mohanavelu S. et al. . Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS–TIMI 46): a randomised, double–blind, phase II trial.  The Lancet. 2009;  374 29-38
    CrossrefPubMedGoogle Scholar
  • 40 Petersen P, Grind M, Adler J.. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose–guiding, tolerability, and safety study.  J Am Coll Cardiol. 2003;  41 1445-1451
    CrossrefPubMedGoogle Scholar
  • 41 Sabatine MS, Antman EM, Widimsky P. et al. .Otamixaban for the treatment of patients with non–ST–elevation acute coronary syndromes (SEPIA–ACS1TIMI 42): a randomised, double–blind, active–controlled, phase 2 trial. The Lancet 2009: 61454-9
    PubMedGoogle Scholar
  • 42 Schulman S, Wählander K, Lundström T. et al. . Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran.  N Engl J Med. 2003;  349 1713-1721
    CrossrefPubMedGoogle Scholar
  • 43 Singer DE, Albers GW, Dalen JE. et al. . Antithrombotic Therapy in Atrial Fibrillation.  CHEST. 2008;  133 546-592
    CrossrefPubMedGoogle Scholar
  • 44 SPORTIF Executive Steering Committee for the SPORTIF V Investigators. . Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrail Figrillation: A randomized trial.  JAMA. 2005;  293 690-698
    CrossrefPubMedGoogle Scholar
  • 45 SPORTIF Executive Steering Committee. . Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non–valvular atrial fibrillation (SPORTIF III): randomised controlled trial.  The Lancet. 2003;  362 1691-1698
    CrossrefPubMedGoogle Scholar
  • 46 The van Gogh Investigators. . Idraparinux versus standard therapy for venous thromboembolic disease.  N Engl J Med. 2007;  357 1094-1104
    CrossrefPubMedGoogle Scholar
  • 47 The van Gogh Investigators. . Extended prophylaxis of venous thromboembolism with idraparinux.  N Engl J Med. 2007;  357 1105-1112
    CrossrefPubMedGoogle Scholar
  • 48 Thiel D, Kalodiki E, Wahi R. et al. . Interpretation of Benefit–Risk of Enoxaparin as Comparator in the RECORD Program: Rivaroxaban Oral Tablets (10 milligrams) for Use in Prophylaxis in Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Hip or Knee Replacement Surgery.  Clin Appl Thromb Hemost. 2009;  15 389-394
    CrossrefPubMedGoogle Scholar
  • 49 Turpie AG, Bauer KA, Davidson BL. et al. . A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).  Thromb Haemost. 2009;  101 68-76
    PubMedGoogle Scholar
  • 50 Turpie AGG, Bauer KA, Davidson B. et al. . Once–daily oral rivaroxaban compared with subcutaneous Enoxaparin every 12 hours for thromboprophylaxis after total knee replacement RECORD 4.  Blood. 2008;  35
    PubMedGoogle Scholar
  • 51 Turpie AG, Lassen MR, Davidson BL. et al. . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.  Lancet. 2009;  373 1673-1680
    CrossrefPubMedGoogle Scholar
  • 52 Wallentin L, Wilcox RG, Douglas W Weaver. et al. . Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.  The Lancet. 2003;  362 789-797
    CrossrefPubMedGoogle Scholar

Korrespondenz

Prof. Dr. med. Job Harenberg

Institut für Klinische Pharmakologie Mannheim Ruprecht–Karls–Universität Heidelberg

Maybachstr. 14

68169 Mannheim

Fax: 0621/383-9622

Email: job.harenberg@medma.uni-heidelberg.de

      >